公开(公告)号：US20240091102A1

公开(公告)日：2024-03-21

申请号：US17754877

申请日：2020-10-16

申请人： Janssen Vaccines & Prevention B.V.

发明人： Olga Labovitiadi ,  Martinus Anne Hobbe Capelle ,  Joao Miguel Calado Da Silva Freire ,  Willem Jan Timmer

IPC分类号： A61J1/14 ,  A61K39/13 ,  A61K39/235

CPC分类号： A61J1/1468 ,  A61K39/13 ,  A61K39/235 ,  A61K2039/5254

摘要： The present invention provides a vaccine product comprising a container, wherein the container comprises an internal surface, the internal surface comprising either (i) silicon dioxide, (ii) a polymeric material, or (iii) a surface treated with ethylene oxide; and a vaccine composition within the container in contact with the internal surface, wherein the vaccine composition comprises virus particles.

公开(公告)号：US11911457B2

公开(公告)日：2024-02-27

申请号：US16967451

申请日：2019-02-06

申请人： BHARAT BIOTECH INTERNATIONAL LIMITED

发明人： Krishna Murthy Ella ,  Vijaya Kumar Daram

IPC分类号： A61K39/395 ,  A61K39/13 ,  C12N7/00 ,  A61K39/00

CPC分类号： A61K39/13 ,  C12N7/00 ,  A61K2039/5252 ,  C12N2770/32634 ,  C12N2770/32652 ,  C12N2770/32663

摘要： The present invention pertains to the field of industrial scale inactivation of various enteroviruses and large and industrial scale production of enterovirus vaccine compositions and combinations of various enteroviruses so obtained.

公开(公告)号：US11680087B2

公开(公告)日：2023-06-20

申请号：US17126712

申请日：2020-12-18

申请人： Pfizer Inc.

发明人： Annaliesa Sybil Anderson ,  Rasappa Gounder Arumugham ,  John Erwin Farley ,  Leah Diane Fletcher ,  Shannon Lea Harris ,  Kathrin Ute Jansen ,  Thomas Richard Jones ,  Lakshmi Khandke ,  Bounthon Loun ,  John Lance Perez ,  Gary Warren Zlotnick

IPC分类号： A61K39/05 ,  C07K14/22 ,  A61K39/00 ,  A61K39/13 ,  A61K39/295 ,  A61K39/095 ,  A61K39/12 ,  A61K39/39 ,  C12N7/00

CPC分类号： C07K14/22 ,  A61K39/0016 ,  A61K39/095 ,  A61K39/12 ,  A61K39/13 ,  A61K39/295 ,  A61K39/39 ,  C12N7/00 ,  A61K2039/5252 ,  A61K2039/545 ,  A61K2039/55505 ,  A61K2039/55511 ,  A61K2039/70 ,  C12N2710/20034 ,  C12N2770/32634 ,  Y02A50/30

摘要： In one aspect, the invention relates to a composition including a first polypeptide having the sequence set forth in SEQ ID NO: 1 and a second polypeptide having the sequence set forth in SEQ ID NO: 2. In one embodiment, the composition includes about 120 μg/ml of a first polypeptide including the amino acid sequence set forth in SEQ ID NO: 1, 120 μg/ml of a second polypeptide including the amino acid sequence set forth in SEQ ID NO: 2, about 2.8 molar ratio polysorbate-80 to the first polypeptide, about 2.8 molar ratio polysorbate-80 to the second polypeptide, about 0.5 mg/ml aluminum, about 10 mM histidine, and about 150 mM sodium chloride. In one embodiment, a dose of the composition is about 0.5 ml in total volume. In one embodiment, two-doses of the composition induce a bactericidal titer against diverse heterologous subfamily A and subfamily B strains in a human.

公开(公告)号：US11273212B2

公开(公告)日：2022-03-15

申请号：US16348803

申请日：2017-11-10

申请人： Sumitomo Dainippon Pharma Co., Ltd. ,  NATIONAL UNIVERSITY CORPORATION EHIME UNIVERSITY

发明人： Akihisa Fukushima ,  Takafumi Tsuboi ,  Eizo Takashima ,  Hikaru Nagaoka

IPC分类号： A61K39/015 ,  A61P33/06 ,  A61K39/05 ,  A61K39/13 ,  C07K14/445 ,  C07K16/20 ,  C12N15/10

摘要： The present invention relates to a polypeptide consisting of an amino acid sequence selected from: (a) the amino acid sequence of SEQ ID NO: 4 or SEQ ID NO: 8, (b) an amino acid sequence that differs from the amino acid sequence of SEQ ID NO: 4 or SEQ ID NO: 8 by substitution, deletion, addition, or insertion of 1 to 10, preferably 1-5, more preferably 1, 2 or 3 amino acids, and (c) an amino acid sequence that has at least 95%, preferably 97%, more preferably 99% sequence identity with the amino acid sequence of SEQ ID NO: 4 or SEQ ID NO: 8, and a malaria vaccine comprising the polypeptide, for example.

公开(公告)号：US20210346483A1

公开(公告)日：2021-11-11

申请号：US17284529

申请日：2019-10-04

申请人： SERUM INSTITUTE OF INDIA PRIVATE LTD

发明人： Inder Jit SHARMA ,  Rakesh KUMAR ,  Jaganathan Semburakkiannan KILVANI ,  Manohar DODDAPANENI ,  Anil Vyankatrao SHITOLE

IPC分类号： A61K39/00 ,  A61K39/29 ,  A61K39/102 ,  A61K39/13 ,  A61K39/295 ,  A61K47/14 ,  A61K47/10 ,  C12N7/00 ,  A61P31/12 ,  A61P31/04

摘要： The present disclosure relates to a fully liquid immunogenic composition comprising a combination of antigens/immunogens. The immunogenic composition comprises optimum amount of antigens/immunogens to confer protection against a number of diseases. The composition exhibits improved immunogenicity and stability. A process for preparing the vaccine composition is also disclosed.

公开(公告)号：US10202423B2

公开(公告)日：2019-02-12

申请号：US14426019

申请日：2013-08-29

申请人： MEDICAGO INC.

发明人： Marc-Andre D'Aoust ,  Pierre-Olivier Lavoie ,  Manon Couture ,  Lucie Poulin ,  Louis-Philippe Vezina

IPC分类号： C07K14/00 ,  C07K14/005 ,  C07K16/10 ,  C12N15/82 ,  A61K39/125 ,  A61K39/13 ,  C12N7/00

摘要： A method of producing a picornavirus-like particle (PVLP) in a plant is provided. The method comprises introducing a first nucleic acid and a second nucleic acid into the plant, portion of the plant, or a plant cell. The first nucleic acid comprising a first regulatory region active in the plant operatively linked to a nucleotide sequence encoding a polyprotein. The second nucleic acid comprises a second regulatory region active in the plant and operatively linked to a nucleotide sequence encoding one or more protease. The plant, portion of the plant, or plant cell is incubated under conditions that permit the expression of the nucleic acids, thereby producing the PVLP. A PVLP comprising the polyprotein is also provided.

公开(公告)号：US10137188B2

公开(公告)日：2018-11-27

申请号：US14765365

申请日：2014-02-05

申请人： University of Georgia Research Foundation, Inc. ,  The United States of America, as represented by the Secretary, Department of Health and Human Services ,  THERMO FISHER SCIENTIFIC INC.

发明人： Jon Michael Karpilow ,  Mark Steven Oberste ,  Ralph A. Tripp ,  Stephen M. Tompkins

IPC分类号： A61K39/395 ,  C07K16/28 ,  C12N5/10 ,  A61K45/06 ,  A61P35/00 ,  A61K39/13 ,  C12N15/11 ,  C12N7/00 ,  C12N15/113

摘要： Provided herein are engineered cell lines. In some embodiments, cells of an engineered cell line have altered expression of a gene and/or altered expression of an miRNA, wherein the altered expression results in increased or decreased production of a virus. The virus is a picornavirus, such as a poliovirus or Enterovirus 71. Also provided herein are methods for using the engineered cells to produce virus, and methods for treating a subject having or at risk of having a viral infection.

公开(公告)号：US20180296614A1

公开(公告)日：2018-10-18

申请号：US15768147

申请日：2016-10-14

申请人： Duke University

发明人： Darell D. Bigner ,  Matthias Gromeier ,  Smita Nair ,  Vidyalakshmi Chandramohan

IPC分类号： A61K35/768 ,  A61K39/13 ,  A61K9/127 ,  A61K39/395 ,  C07K16/28 ,  A61P35/00 ,  C12N15/85

CPC分类号： A61K35/768 ,  A61K9/127 ,  A61K39/13 ,  A61K39/39 ,  A61K39/39541 ,  A61K2039/505 ,  A61K2300/00 ,  A61P35/00 ,  C07K16/2818 ,  C07K2317/76 ,  C12N7/00 ,  C12N15/85 ,  C12N2770/32621 ,  C12N2770/32632 ,  C12N2840/203 ,  Y02A50/466

摘要： Human clinical use of a chimeric poliovirus construct has demonstrated excellent anti-tumor effect. Combination with immune checkpoint inhibitors increases the anti-tumor effect. Tumors of different types are susceptible to the combination treatment, including but not limited to melanoma, glioglastoma, renal cell carcinoma, prostate cancer, breast cancer, lung cancer, medulloblastoma, and colorectal cancer.

公开(公告)号：US20180104324A1

公开(公告)日：2018-04-19

申请号：US15819312

申请日：2017-11-21

申请人： GLAXOSMITHKLINE BIOLOGICALS SA

发明人： Guido Grandi ,  Immaculada Margarit Y Ros ,  Domenico Maione

IPC分类号： A61K39/09 ,  A61K39/13 ,  A61K9/00 ,  A61K39/00 ,  A61K39/05 ,  A61K39/08 ,  A61K39/02 ,  C12N7/00 ,  A61K39/12

CPC分类号： A61K39/092 ,  A61K9/0019 ,  A61K39/0018 ,  A61K39/05 ,  A61K39/08 ,  A61K39/099 ,  A61K39/12 ,  A61K39/13 ,  A61K47/646 ,  A61K2039/55 ,  A61K2039/55505 ,  A61K2039/6037 ,  A61K2039/70 ,  C12N7/00 ,  C12N2770/32334 ,  C12N2770/32634 ,  Y02A50/466

摘要： Methods for raising an immune response in a mammal, by administration of an immunogenic composition comprising capsular saccharides from Streptococcus agalactiae (GBS) serotypes conjugated to carrier proteins.

公开(公告)号：US20180055924A1

公开(公告)日：2018-03-01

申请号：US15795545

申请日：2017-10-27

申请人： De Staat der Nederlanden, Vert. Door De Minister Van VWS Ministerie van Volksgezondheid, Welzijn en

发明人： Heleen KRAAN ,  Jean-Pierre AMORIJ

IPC分类号： A61K39/13 ,  C12N7/00 ,  A61K9/19 ,  A61K47/26 ,  A61K47/18 ,  A61K47/02

CPC分类号： A61K39/13 ,  A61K9/19 ,  A61K39/12 ,  A61K47/02 ,  A61K47/183 ,  A61K47/26 ,  C12N7/00 ,  C12N2770/32634 ,  Y02A50/466

摘要： The present invention relates to methods for producing dried formulations of biopharmaceutical agents that aim to minimize the loss of activity of the agents upon drying and to provide dried formulations with an extended shelf life. The method comprises the step of drying an aqueous solution comprising, in addition to the biopharmaceutical agent, at least an amino acid, a polyol and a metal salt. Preferably the amino acid is glutamate, the polyol is sorbitol and optionally also mannitol and the metal salt is a magnesium salt. The solution is dried by vacuum drying or by lyophilization. The methods are particularly useful for preparing dried formulations of viruses such as poliovirus or respiratory syncytial virus to be used for vaccination. The invention also relates to dried formulations prepared in accordance with the methods of the invention and to their use as medicaments, e.g. as vaccines.